EMA/710110/2017

European Medicines Agency decision

P/0373/2017

of 1 December 2017

on the agreement of a paediatric investigation plan and on the granting of a deferral for synthetic double-stranded siRNA oligonucleotide directed against hydroxyacid oxidase 1 mRNA that is covalently linked to a ligand containing three N-acetylgalactosamine residues (ALN-GO1) (EMEA-002079-PIP01-16) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Contact EMA www.ema.europa.eu/contact

European Medicines Agency decision

P/0373/2017

of 1 December 2017

on the agreement of a paediatric investigation plan and on the granting of a deferral for synthetic double-stranded siRNA oligonucleotide directed against hydroxyacid oxidase 1 mRNA that is covalently linked to a ligand containing three N-acetylgalactosamine residues (ALN-GO1) (EMEA-002079-PIP01-16) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Alnylam UK Limited on 12 September 2016 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 13 October 2017, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for synthetic double-stranded siRNA oligonucleotide directed against hydroxyacid oxidase 1 mRNA that is covalently linked to a ligand containing three N-acetylgalactosamine residues (ALN-GO1), solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for synthetic double-stranded siRNA oligonucleotide directed against hydroxyacid oxidase 1 mRNA that is covalently linked to a ligand containing three N-acetylgalactosamine residues (ALN-GO1), solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Alnylam UK Limited, Braywick Gate, Braywick Road, SL6 1DA – Maidenhead, United Kingdom.

EMA/PDCO/471970/2017
London, 13 October 2017

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral

EMEA-002079-PIP01-16

Scope of the application

Active substance(s):

Synthetic double-stranded siRNA oligonucleotide directed against hydroxyacid oxidase 1 mRNA that is covalently linked to a ligand containing three N-acetylgalactosamine residues (ALN-GO1)

Condition(s):

Treatment of hyperoxaluria

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

Alnylam UK Limited

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Alnylam UK Limited submitted for agreement to the European Medicines Agency on 12 September 2016 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation.

The procedure started on 18 October 2016.

Supplementary information was provided by the applicant on 24 July 2017. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable

2. Paediatric investigation plan

2.1. Condition

Treatment of hyperoxaluria

2.1.1. Indication(s) targeted by the PIP

Treatment of primary hyperoxaluria type 1

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for injection

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	**Study 1** Development of a solution with a concentration of less than 200 mg/mL
Non-clinical studies	1	**Study 2** 4-week dose range-finding toxicity study in neonate and juvenile rats
Clinical studies	5	**Study 3** Single (subject/patient) blind, randomised, placebo controlled trial to evaluate safety, tolerability pharmacokinetics and pharmacodynamics of ALN-GO1 in healthy adult subjects, and patients (children from 6 years of age (and adults) with primary hyperoxaluria type 1 (PH1)) **Study 4** Open-label extension study for patients who previously participated in ALN-GO1 clinical studies including Study 3 (ALN-GO1-001), Study 5 (ALN-GO1-003) and Study 6 (ALN-GO1-004) **Study 5** Double-blind, randomised, placebo controlled trial to evaluate efficacy, safety, pharmacokinetics and pharmacodynamics of ALN-GO1 in children from 6 years of age (and adults) with primary hyperoxaluria type 1 (PH1) and relatively intact renal function

Area	Number of measures	Description
		Study 6 Open-label, uncontrolled trial to evaluate safety, pharmacokinetics and pharmacodynamics of ALN-GO1 in children from birth to less than 6 years of age with primary hyperoxaluria type 1 (PH1) and relatively intact renal function **Study 7** Open-label, uncontrolled trial to evaluate safety, pharmacokinetics and pharmacodynamics of ALN-GO1 in children from birth to less than 18 years of age (and adults) with primary hyperoxaluria type 1 (PH1) with impaired renal function including those on dialysis
Extrapolation, modelling and simulation studies	2	**Study 8** Modelling and simulation study to evaluate the use of the product and support dose selection for the treatment of primary hyperoxaluria type 1 (PH1) in children from 6 years of age with relatively intact renal function **Study 9** Modelling and simulation study to evaluate the use of the product and support dose selection for the treatment of primary hyperoxaluria type 1 (PH1) in children from birth to less than 6 years of age with relatively intact renal function
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By October 2022
Deferral for one or more measures contained in the paediatric investigation plan:	Yes